Galician
English
Afrikaans
Albanian
Arabic
Armenian
Azerbaijani
Basque
Belarusian
Bulgarian
Catalan
Chinese (Simplified)
Chinese (Traditional)
Croatian
Czech
Danish
Dutch
Estonian
Filipino
Finnish
French
Galician
Georgian
German
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Malay
Maltese
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Thai
Turkish
Ukrainian
Urdu
Vietnamese
Welsh
Yiddish
Aspectos destacados do 15o Congreso Anual de EAHAD
Análise final do ensaio fundamental de terapia xénica HOPE-B de fase 3: eficacia e seguridade estables do etranacogene Dezaparvovec en adultos con hemofilia B grave ou moderadamente grave
Wolfgang Miesbach1; Frank WGLeebeek2; Michael Recht3; Nigel S. Key4; Susan Lattimore3; Giancarlo Castaman5; Michael Coppens6; David Cooper7; Sergio Slawka7; Stephanie Verweij7; Robert Gut7; Ricardo Dolmetsch7; Yanyan Li8; Paul E. Monahan8; Steven W. Pipe9
Investigadores HOPE-B1; Hospital Universitario de Frankfurt, Frankfurt, Alemania2; Erasmus MC, University Medical Center Rotterdam, Holanda3; Oregon Health & Science University, Portland, OR, Estados Unidos4; University of North Carolina, Chapel Hill, NC, Estados Unidos5; Centro de trastornos hemorrágicos e coagulación, Hospital Universitario Careggi, Florencia, Italia6; Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands7; uniQureBV, Amsterdam, Países Baixos/uniQure Inc. Lexington, MA, EUA8; CSL Behring, Rei de Prusia, PA, Estados Unidos9; Universidade de Michigan, Ann Arbor, MI, Estados Unidos
CONTIDO RELACIONADO
